Research location
Zwickau
Saxony, Germany
Advertisement
Research activity in Zwickau
Saxony, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Zwickau
9 linked trials · page 1 of 1A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettINGNCT06712628 · 2024-11-07 · 1 site observation
RECRUITING
Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast CancerNCT04495309 · 2021-03-05 · 1 site observation
COMPLETED
Effects of Different Types of Exercise Interventions in Patients With Type 2 DiabetesNCT01377558 · 2011-04-01 · 1 site observation
UNKNOWN
Effects of Exercise Intervention and Rehabilitation Exercise Intervention in Patients With Type 2 DiabetesNCT01393275 · 2010-02-01 · 1 site observation
COMPLETED
ARI103094-Follow-Up Study for REDUCE Study SubjectsNCT00883909 · 2009-04-09 · 1 site observation
COMPLETED
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast CancerNCT00558103 · 2007-12-01 · 1 site observation
COMPLETED
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung CancerNCT00480025 · 2007-10-04 · 1 site observation
TERMINATED
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast CancerNCT00374322 · 2006-08-01 · 1 site observation
COMPLETED
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskNCT00056407 · 2003-03-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.